Engine Capital Management, Lp Buys 13,061 Shares of Orthofix Medical (NASDAQ:OFIX) Stock

Orthofix Medical Inc. (NASDAQ:OFIX) major shareholder Engine Capital Management, Lp purchased 13,061 shares of the firm’s stock in a transaction on Wednesday, February 25th. The stock was bought at an average cost of $12.96 per share, with a total value of $169,270.56. Following the acquisition, the insider owned 3,673,092 shares of the company’s stock, valued at approximately $47,603,272.32. The trade was a 0.36% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

Engine Capital Management, Lp also recently made the following trade(s):

• On Tuesday, February 24th, Engine Capital Management, Lp bought 124,797 shares of Orthofix Medical stock. The shares were acquired at an average price of $12.55 per share, for a total transaction of $1,566,202.35.

Orthofix Medical Stock Up 2.7%

Shares of OFIX opened at $13.53 on Friday. The firm has a market cap of $535.79 million, a P/E ratio of -5.78 and a beta of 0.78. Orthofix Medical Inc. has a 12 month low of $10.24 and a 12 month high of $18.66. The stock’s 50 day moving average is $14.08 and its two-hundred day moving average is $14.70. The company has a current ratio of 2.45, a quick ratio of 1.38 and a debt-to-equity ratio of 0.39.

Orthofix Medical (NASDAQ:OFIX) last posted its quarterly earnings data on Tuesday, February 24th. The medical device company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.44 by ($0.50). The firm had revenue of $219.91 million during the quarter, compared to analyst estimates of $218.72 million. Orthofix Medical had a negative return on equity of 20.38% and a negative net margin of 11.21%. Analysts predict that Orthofix Medical Inc. will post -2.81 earnings per share for the current fiscal year.

More Orthofix Medical News

Here are the key news stories impacting Orthofix Medical this week:

• Positive Sentiment: Engine Capital (a major shareholder) bought shares in two recent transactions — ~124,797 shares at ~$12.55 on Feb. 24 and an additional 13,061 shares at ~$12.96 on Feb. 25 — increasing its stake and signaling confidence from a large institutional holder. Engine Capital purchases OFIX shares
• Neutral Sentiment: Analysts trimmed price targets but kept several constructive ratings: Canaccord cut its target from $24 to $20 (still a “buy”) and others reduced targets modestly; consensus remains mixed (roughly a mid‑teens/$18-ish average target). This lowers upside expectations but does not indicate a broad teardown of the bull case. Analyst notes and price-target changes
• Negative Sentiment: Q4 results missed on EPS: reported ($0.06) vs. $0.44 expected; revenue was roughly in line but margins and ROE were negative — the EPS shortfall triggered investor selling and increased near-term skepticism. Shares down after earnings miss
• Negative Sentiment: Management flagged margin delays and issued revised 2026 guidance that shifts the narrative toward execution risk; until margin recovery and guidance clarity appear, the stock faces headwinds. Narrative shifting: margin delays and guidance

Institutional Investors Weigh In On Orthofix Medical

A number of hedge funds have recently bought and sold shares of the stock. AQR Capital Management LLC grew its stake in shares of Orthofix Medical by 67.7% during the first quarter. AQR Capital Management LLC now owns 20,409 shares of the medical device company’s stock worth $333,000 after purchasing an additional 8,241 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Orthofix Medical by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,561 shares of the medical device company’s stock worth $335,000 after buying an additional 1,213 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of Orthofix Medical during the 1st quarter worth about $1,076,000. Strs Ohio acquired a new position in shares of Orthofix Medical during the 1st quarter worth about $150,000. Finally, AlphaQuest LLC increased its holdings in shares of Orthofix Medical by 18.4% in the 2nd quarter. AlphaQuest LLC now owns 29,827 shares of the medical device company’s stock valued at $333,000 after acquiring an additional 4,625 shares during the last quarter. Institutional investors and hedge funds own 89.76% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on OFIX shares. Canaccord Genuity Group reduced their target price on shares of Orthofix Medical from $24.00 to $20.00 and set a “buy” rating on the stock in a research note on Thursday. Barrington Research cut their price target on shares of Orthofix Medical from $18.00 to $17.00 and set an “outperform” rating for the company in a report on Wednesday. TD Cowen initiated coverage on Orthofix Medical in a report on Tuesday, January 27th. They issued a “hold” rating and a $14.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Orthofix Medical in a research report on Thursday, January 22nd. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Orthofix Medical currently has an average rating of “Hold” and a consensus target price of $18.25.

About Orthofix Medical

Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company’s core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.

Orthofix’s product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.